News
02-14-2012, 05:12 AM
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. Researchers are therefore seeking ways to enhance the effectiveness of trastuzumab...
More... (http://www.medicalnewstoday.com/releases/241601.php)
More... (http://www.medicalnewstoday.com/releases/241601.php)